BC Hepatitis Network

Email

hello@bchep.org

Phone

1-888-411-7578

Web

bchep.org

Address

Room 20 – 1139 Yates Street, Victoria, BC AB V8V 3N2 Canada
About BC Hepatitis Network

BC Hepatitis Network provides hepatitis education, peer-to-peer support, peer mentorship and training, hepatitis C screening & linking to care event support, connection to services, and advocacy. We work with people living with hepatitis and others affected, and partner with community-based organizations and government to address concerns about hepatitis prevention, care, treatment access and support.
BC Hepatitis Network also supports work addressing:

  • criminalization of people who use drugs
  • poisoned drug supply/overdose crisis
  • housing
  • mental health and addiction services
  • human rights
  • BC Hepatitis Network acknowledges that we work within the ancestral, traditional and unceded territories of diverse First Nations of what is often referred to as British Columbia.
    Our Vision
    BC free from new hepatitis B and hepatitis C infections, with the best possible care and support for those already infected.
    Our Mission
    To provide a means for sharing information and coordinating mutual support and action that will strengthen the capacity of individuals and organizations throughout British Columbia to prevent new hepatitis B and hepatitis C infections and to improve the health and treatment outcomes of people already living with hepatitis B or hepatitis C.
    How We Work
    BC Hepatitis Network works in partnership and collaboration with individuals (people with lived and living experience of viral hepatitis, interested community members), community-based organizations, health care providers, health authorities and government to improve hepatitis B and hepatitis C prevention, care, treatment access and support in BC, and address stigma in health care.
    BC Hepatitis Network also offers a free and confidential peer-to-peer support and information helpline, Help4Hep BC.

Sign up to receive updates from WHA

Name(Required)
I would like to hear about(Required)

We use Mailchimp as our marketing platform. By clicking below to subscribe, you acknowledge that your information will be transferred to Mailchimp for processing. Learn more about Mailchimp's privacy practices.

Hepatitis and PWID/harm reduction 

 

11:35 – 11:40  

Chair: WHO – Intro and set the scene.  

 

11:40 – 11:55  

Co-chair:  EMCDDA – Monitoring viral hepatitis elimination among PWID in Europe. 

 

11:55 – 12:00 

ID 29: Ema Pos (not yet registered) 

Title: If the mountain won’t come to Mohammed: lessons from a decentralized Infectious Disease consultation. 

 

12:05 – 12:10  

ID 152: Brian Conway (Registered in person) 

Title: Community Pop-up Clinic: Cascade of Care and HCV Treatment of Vancouver’s inner-city PWID Populations.

 

12:10 – 12:15 

ID 212: Jasmine West (not yet registered) 

Title: From lived experience to lived expertise: a syndemic approach. 

 

12:15 – 12:20 

ID: 299 Mercy Nyakowa (Registered in person) 

Title: HCV and HBV prevalence and associated risk factors among people who inject drugs (PWIDs) in Kenya 

 

12:20 – 12:25 

ID: 133 Nalinikanta Rajkumar (Registered in person) 

Title: Rapid regimen of HBV vaccination: Does it work for high risk groups?  

 

12:25 – 12:30 

Q&A and closing remarks   

tHIS

 

IS 

 

BEN’S

 

 

 

BIG 

 

 

TEST

effective case finding strategies

Supported by Vir Biotechnology, Inc

During this session you will hear from hepatitis Delta expert, Dr. Maria Buti, and a patient who has lived with hepatitis Delta in a panel discussion moderated by Dr. Carey Hwang, Chief Medical Officer (interim) of Vir Biotechnology. This panel will inform perspectives on patient needs, opportunities for enhanced screening, and strengthening linkages to care.

Session Agenda

14:40 – 14:45    

Panel overview and introductions facilitated by Dr Carey Hwang (Vir Biotechnology)

14:45 – 15:05   

Panel discussion: Dr Maria Buti (University Hospital Vall d’Hebron, Spain), Milanka Barbosa, Dr Carey Hwang (Chief Medical Officer interim), Vir Biotechnology

15:05 – 15:10    

Final remarks and close